非转移性去势抵抗性前列腺癌:现代视角
本文综述非转移性去势抵抗性前列腺癌(nmCRPC)的诊疗现状,指出目前尚无FDA批准的治疗方案,但氟环洛芬PET-CT和Ga-PSMA PET-CT等新型影像技术正提高诊断准确性,并有3项关于第二代抗雄激素的临床试验正在进行,有望带来新的治疗范式。
要点
- nmCRPC目前尚无FDA批准的治疗方案。
- 氟环洛芬PET-CT和Ga-PSMA PET-CT等新型影像技术提高诊断准确性。
- 3项第二代抗雄激素治疗nmCRPC的临床试验正在进行。
核心结论
- 新型影像技术提高nmCRPC诊断准确性,第二代抗雄激素临床试验有望带来新治疗范式。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 目前尚无FDA批准的nmCRPC治疗方案。
- 氟环洛芬PET-CT和Ga-PSMA PET-CT等新型影像技术正在提高诊断准确性。
- 有3项正在进行的临床试验研究第二代抗雄激素用于nmCRPC。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm. In this article, we will review the new imaging techniques and the rationale behind novel treatment modalities in nmCRPC.
引用
- Cancian M, Renzulli JF. Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective. Urology. 2018. PMID: 29357298. doi:10.1016/j.urology.2018.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。